Is Trofex a possible “replacement” imaging agent for Combidex?

Posted on October 15, 2010 by Sitemaster

According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection.

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , , | 2 Comments »

PSMA protein targeting agent and metastatic disease

Posted on June 17, 2009 by Sitemaster

According to a company press release, Molecular Insight Pharmaceuticals, Inc. presented clinical data earlier today on a development-stage, radiolabeled, small-molecule, molecular imaging pharmaceutical with potential in the diagnosis, staging, and perhaps even the treatment of advanced forms of prostate cancer.

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , , , , | 6 Comments »

Follow

Get every new post delivered to your Inbox.

Join 268 other followers